Market Overview

UPDATE: Longbow Upgrades Chemtura to Buy on Margin Enhancement and Portfolio Evolution

Share:
Related CHMT
Benzinga's Top Upgrades
KeyBanc On Specialty Chemicals: Upgrades Chemtura, Innospec To Overweight

Longbow raised its rating on Chemtura (NYSE: CHMT) from Neutral to Buy with a $26 price target.

Longbow commented, "We are upgrading our investment rating of CHMT to BUY from NEUTRAL with a 12-month target price of $26 on greater confidence in management's ability to outperform expectations in the near-term. Sustainable improvements in AgroSolutions, a compelling strategic rationale for the Solaris deal and expectations of further growth in Engineered Products, combined with further portfolio optimization should generate meaningful shareholder value expansion over a 12-24 month period."

Chemtura closed at $20.44 on Wednesday.

Latest Ratings for CHMT

DateFirmActionFromTo
Apr 2016BB&T CapitalUpgradesHoldBuy
Apr 2016KeyBancUpgradesSector WeightOverweight
Oct 2015Seaport Global SecuritiesUpgradesBuy

View More Analyst Ratings for CHMT
View the Latest Analyst Ratings

Posted-In: LongbowAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (CHMT)

View Comments and Join the Discussion!